SenzaGen

SenzaGen's mission is to advance and commercialize non-animal methods for predictive toxicology, with a core focus on skin sensitization. The company has successfully commercialized its GARD®skin assay, which is an OECD-adopted (TG 442E, 497) regulatory test, and operates a GLP-compliant service laboratory for global clients. Its strategy is to leverage its validated platform to expand into adjacent toxicity endpoints, such as respiratory sensitization with GARD®air, and to deepen its service offerings with quantitative potency assessments to support next-generation risk assessment (NGRA).

The GARD® (Genomic Allergen Rapid Detection) platform integrates a human dendritic-like cell line (SenzaCell®), genomic biomarker signatures, and machine learning to provide mechanism-based, high-accuracy in vitro tests for predictive toxicology endpoints like skin and respiratory sensitization.

SenzaGen competes with other OECD-adopted in vitro tests for skin sensitization (e.g., DPRA, KeratinoSens, h-CLAT) and the large CROs that offer them. Its key differentiation is the holistic, genomics-based GARD platform, which offers higher reported accuracy and broader applicability than single-mechanism assays or traditional integrated testing strategies.